Post

Marinus fails to meet early stopping criteria for status epilepticus trial

Marinus Pharmaceuticals has announced that its pivotal Phase III RAISE study (NCT04391569) of IV ganaxolone for the treatment of status …

IT and bioinformatics companies for the clinical trials industry

Digitalising clinical trials can improve accessibility and engagement for participants, as well as data collection and analytics. It has the …

Sanofi advances NK cell engager to Phase II for blood cancer treatment

Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use …

EMulate’s radiofrequency device proves effective in GBM mouse models 

Seattle-based device company EMulate Therapeutics has announced that a study proving the effectiveness of its radiofrequency energy device in mouse …

MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement

Lyon, France-based MaaT Pharma has announced positive 18-month data for its lead candidate MaaT013 showing an overall survival advantage in …